References

Head and neck cancer.

10.1056/nejmra1715715 · 2020 · External reference

Cancer statistics, 2024.

10.3322/caac.21820 · 2024 · External reference

Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors.

10.1093/annonc/mds299 · 2012 · External reference

The promise of neoadjuvant immunotherapy and surgery for cancer treatment.

10.1158/1078-0432.ccr-18-2641 · 2019 · External reference

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

10.1016/s0140-6736(18)31999-8 · 2019 · External reference

Nivolumab for recurrent squamous-cell carcinoma of the head and neck.

10.1056/nejmoa1602252 · 2016 · External reference

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis.

10.1016/j.jtho.2024.09.1443 · 2025 · External reference

Pathologic treatment effect and survival in HPV-negative HNSCC following neoadjuvant nivolumab.

10.1001/jamaoto.2025.1707 · 2025 · External reference

Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer.

10.1056/nejmoa2415434 · 2025 · External reference

Neoadjuvant chemoimmunotherapy in patients with locally advanced squamous head and neck cancer: a retrospective study.

10.3389/fonc.2025.1576800 · 2025 · External reference

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).

10.1097/js9.0000000000000489 · 2023 · External reference

Evaluation of neoadjuvant immunotherapy regimens for head and neck squamous cell carcinoma: a systematic review and single-arm and network meta-analysis.

10.1097/js9.0000000000004689 · 2026 · External reference

Neoadjuvant immunotherapy and chemoimmunotherapy regimens in head and neck cancer: a systematic review and meta-analysis.

10.1001/jamaoto.2026.0080 · 2026 · External reference

Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials.

10.1016/j.ejca.2023.03.010 · 2023 · External reference

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

10.1016/s0140-6736(13)62422-8 · 2014 · External reference

Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.

10.1158/1078-0432.ccr-25-2807 · 2025 · External reference

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.

10.1016/s0140-6736(25)01850-1 · 2026 · External reference

Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

10.1200/jco.2012.47.7802 · 2013 · External reference

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

10.1002/14651858.cd006386.pub4 · 2021 · External reference

Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311).

10.1200/jco.21.01752 · 2022 · External reference

Transoral robotic surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO Guideline.

10.1200/jco-24-02755 · 2025 · External reference

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial.

10.1016/s1470-2045(25)00324-9 · 2025 · External reference

Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery.

10.1097/sla.0000000000004238 · 2022 · External reference

Neoadjuvant chemotherapy in triple negative breast cancer: a systematic review of breast and node pathologic response.

10.1002/jso.70213 · 2026 · External reference

Modern pathology-driven strategies in neoadjuvant immunotherapy for head and neck squamous cell carcinoma: from residual tumor quantification to spatial and AI-based biomarkers.

10.3390/cancers18061020 · 2026 · External reference

Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer.

10.1016/j.cell.2017.10.044 · 2017 · External reference

Comparison of PD-L1 expression in head and neck squamous cell carcinoma among preoperative biopsy, surgical resection and metastatic lymph node.

10.3389/fonc.2025.1666078 · 2025 · External reference

Pathologic response and survival after neoadjuvant immunotherapy for resectable mucosal HNSCC: a systematic review and meta-analysis.

10.1001/jamaoto.2025.4573 · 2026 · External reference

Discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect.

10.3389/fonc.2020.566315 · 2020 · External reference

670P Discordant pathologic tumor response in primary tumors and lymph nodes after neoadjuvant immune checkpoint inhibition (ICI) in head and neck squamous cell carcinoma (HNSCC).

10.1016/j.annonc.2022.07.794 · 2022 · External reference

Safety of neoadjuvant immunotherapy in resectable cancers: a meta-analysis.

10.3389/fimmu.2022.802672 · 2022 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

External reference